Roche Holding 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가	CHF 371.80
52주 최고가	CHF 374.90
52주 최저가	CHF 252.20
베타	0.35
1개월 변동	11.38%
3개월 변동	11.15%
1년 변동	41.64%
3년 변동	42.92%
5년 변동	1.65%
IPO 이후 변동	1,324.52%

최근 뉴스 및 업데이트

내러티브 업데이트 • Aug 10

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Analysts have lifted their fair value estimate for Roche Holding to CHF 370.31 from CHF 359.22, citing a combination of visible growth, incremental pipeline contributions including giredestrant, and recent partnership activity. They view these factors as supporting revenue growth assumptions and profit margin resilience, despite a slightly higher discount rate and a modestly lower future P/E multiple.

분석 기사 • Jul 31

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Investors signalled that they were pleased with Roche Holding AG's ( VTX:ROP ) most recent earnings report. According...

Recent updates

내러티브 업데이트 • Aug 10

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

분석 기사 • Jul 31

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Investors signalled that they were pleased with Roche Holding AG's ( VTX:ROP ) most recent earnings report. According...

내러티브 업데이트 • Jul 27

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analysts lifted their fair value estimate for Roche Holding, implying a new price target of about CHF 260. They incorporated updated assumptions on revenue growth, margins and P/E following a series of partnership-focused research notes around the company's Nurix collaboration and a recent HSBC rating change.

분석 기사 • Jul 27

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Investors in Roche Holding AG ( VTX:ROP ) had a good week, as its shares rose 7.1% to close at CHF355 following the...

내러티브 업데이트 • Jul 10

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Analysts have modestly lifted their fair value estimate for Roche Holding to CHF 359.22 from CHF 352.00, citing updated assumptions around revenue growth, profit margins and future P/E, along with mixed but generally constructive readthroughs from recent pipeline and partnership research. Analyst Commentary Recent Street research around Roche Holding points to a mixed but constructive setup, with optimism around specific products and partnerships balanced by more cautious views on the risk and timing of future growth and execution.

내러티브 업데이트 • Jun 26

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Analysts have updated their fair value estimate for Roche Holding to CHF 253.81 from CHF 295.00, reflecting refreshed assumptions on revenue growth, margins, and future P/E multiples in light of recent co-development agreements with partners such as Nurix Therapeutics. Analyst Commentary Recent Street research around Roche Holding and its partners gives you a mixed picture, with enthusiasm for the co-development agreements alongside more cautious voices highlighting execution and valuation risks.

새로운 내러티브 • May 12

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

새로운 내러티브 • Apr 19

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Catalysts About Roche Holding Roche is a global healthcare company focused on pharmaceuticals and diagnostics across oncology, neurology, immunology, ophthalmology and cardiometabolic diseases. What are the underlying business or industry changes driving this perspective?

새로운 내러티브 • Apr 04

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Catalysts About Roche Holding Roche Holding is a global healthcare company with large pharmaceutical and diagnostics businesses focused on prescription medicines, biologics and lab testing solutions. What are the underlying business or industry changes driving this perspective?

새로운 내러티브 • Mar 21

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Catalysts About Roche Holding Roche Holding is a global healthcare group focused on pharmaceuticals and diagnostics, with a large late stage pipeline and extensive manufacturing and R&D infrastructure. What are the underlying business or industry changes driving this perspective?

주주 수익률

	ROP	CH Pharmaceuticals	CH 시장
7D	2.6%	1.7%	-1.1%
1Y	41.6%	32.4%	14.7%

수익률 대 산업: ROP은 지난 1년 동안 32.4%의 수익을 기록한 Swiss Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: ROP은 지난 1년 동안 14.7%를 기록한 Swiss 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is ROP's price volatile compared to industry and market?
ROP volatility
ROP Average Weekly Movement	3.7%
Pharmaceuticals Industry Average Movement	4.3%
Market Average Movement	4.0%
10% most volatile stocks in CH Market	7.4%
10% least volatile stocks in CH Market	2.0%

안정적인 주가: ROP는 지난 3개월 동안 Swiss 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: ROP의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.

회사 소개

설립	직원 수	CEO	웹사이트
1896	103,249	Thomas Schinecker	www.roche.com

Roche Holding AG는 유럽, 북미, 라틴 아메리카, 아시아, 아프리카, 호주, 뉴질랜드에서 제약 및 진단 사업을 영위하고 있습니다. 빈혈, 혈액 및 고형 종양, 피부과, 혈액학, 감염성 질환, 염증 및 자가 면역, 신경 장애, 안과, 호흡기 질환, 이식 등의 치료 분야에서 제약 솔루션을 제공합니다. 또한 암, 당뇨병, 코로나19, 간염, 인유두종 바이러스 등 다양한 질병의 진단을 위한 체외 검사, 진단 기기, 디지털 건강 솔루션도 제공합니다.

Roche Holding AG 기초 지표 요약

Roche Holding의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
ROP 기초 통계
시가총액	CHF 296.69b
순이익 (TTM)	CHF 12.34b
매출 (TTM)	CHF 62.96b

24.0x

주가수익비율(P/E)

4.7x

주가매출비율(P/S)

ROP는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
ROP 손익계산서 (TTM)
매출	CHF 62.96b
매출원가	CHF 16.26b
총이익	CHF 46.70b
기타 비용	CHF 34.35b
순이익	CHF 12.34b

최근 보고된 실적

Jun 30, 2026

다음 실적 발표일

Oct 22, 2026

주당순이익(EPS)	15.49
총이익률	74.17%
순이익률	19.60%
부채/자본 비율	86.6%

ROP의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

배당

2.6%

현재 배당 수익률

63%

배당 성향

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/08/20 10:17
종가	2026/08/20 00:00
수익	2026/06/30
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Roche Holding AG는 44명의 분석가가 다루고 있습니다. 이 중 18명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research
Mark Purcell	Barclays

Roche Holding (ROP) 주식 개요

강점

위험 분석

Analyst Price Targets

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Top Community Narratives

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Top Community Narratives

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Top Analyst Narratives

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Roche Holding AG 경쟁사

Novartis

Galderma Group

Sandoz Group

Dottikon ES Holding

가격 이력 및 성과

최근 뉴스 및 업데이트

Genentech to Expand Hillsboro Facility With $750 Million Investment for Advanced Injectables

Genentech Reaches Construction Milestone for $2 Billion North Carolina Biomanufacturing Facility

ChemoMetec and Roche Team Up on Cedex Bio Analyzer Integration Collaboration

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Roche Holding Teams With Evexta Bio for Phase 1b Breast Cancer Drug Trial

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Recent updates

Genentech to Expand Hillsboro Facility With $750 Million Investment for Advanced Injectables

Genentech Reaches Construction Milestone for $2 Billion North Carolina Biomanufacturing Facility

ChemoMetec and Roche Team Up on Cedex Bio Analyzer Integration Collaboration

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Roche Holding Teams With Evexta Bio for Phase 1b Breast Cancer Drug Trial

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Roche Gains FDA Clearance for cobas BV/CV Molecular Vaginitis Diagnostic

First half 2026 earnings released

CHMP Backs EU Approval for Susvimo Continuous Eye Treatment in Roche Milestone

Roche Receives Positive CHMP Recommendation For Susvimo For Neovascular Age-Related Macular Degeneration

Roche Receives FDA Clearance For The Cobas BV/CV Assay Enabling Fast And Highly Accurate Vaginitis Diagnosis

Roche Names Dan Malarek CEO of Diagnostics North America as Leadership Team Shifts

FDA Sets Priority Review for Roche’s Gazyva in Rare Kidney Disease Therapy Decision

Roche Announces FDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Adults with Primary Membranous Nephropathy

Roche Unveils First Fully Automated HDV Test for Severe Hepatitis Detection and Monitoring

Roche Introduces Cobas Hepatitis D Virus Test for Use on Cobas 5800/6800/8800 Systems

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Roche Receives CE Mark for Automated Tuberculosis Blood Test Across Europe

Roche Presents New Data in Alzheimer’S Disease Portfolio At Aaic 2026

Roche Reports Positive Results from Phase Iii Krascendo 1 Study Evaluating Divarasib Against Approved Kras G12c Inhibitors in Previously Treated Kras G12c Non-Small Cell Lung Cancer

FDA Accepts Priority Review for Roche Enspryng in Thyroid Eye Disease Expansion

Roche Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Enspryng for Thyroid Eye Disease

Roche Announces Launch Of AXELIOS 1 Sequencing Platform

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Roche Backs Orano Med to Advance Lead-212 Radiopharma Cancer Therapies

Roche Receives FDA Acceptance for Supplemental Biologics License Application For Lunsumio And Polivy Combination For Relapsed Or Refractory Large B-Cell Lymphoma

Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living with Prostate Cancer

Roche Expands Cancer Diagnostics and Awaits FDA Decision on Tecentriq for Colon Cancer

Roche Announces FDA Grants Priority Review For Roche's Tecentriq For A Certain Type Of Stage III Colon Cancer

Roche Advances Breast Cancer Pipeline With FDA Review for Giredestrant and Companion Diagnostic Approval

Roche Receives FDA Acceptance For New Drug Application For Giredestrant In ER-Positive Early-Stage Breast Cancer

Foundation Medicine Receives Fda Approval for Foundationone Cdx as Companion Diagnostic for Itovebi (Inavolisib) in Combination with Palbociclib and Fulvestrant

Roche Launches the Liver Disease Panel Suite of Certified Algorithms to Support Chronic Liver Disease Management

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Roche Receives CE Mark For Elecsys Ptau217 Blood Test For Alzheimer’S Disease Pathology

Roche Holding AG (SWX:ROP) entered into a definitive merger agreement to acquire PathAI, Inc. for $1.1 billion.

Roche Showcases Ophthalmology Portfolio At Arvo 2026

Roche Announces FDA Acceptance of Application for Gazyva Gazyvaro for Treatment of Systemic Lupus Erythematosus

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Roche Receives CE Mark for New Elecsys NfL Blood Test to Detect Neuroinflammation in Multiple Sclerosis

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Insufficient new directors

Roche Launches the Cobas MPX-E Assay, A New 4-In-1 Donor Screening Test

Roche Launches the Cobas Eplex Respiratory Pathogen Panel 3

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Roche Holding AG to Report Q1, 2026 Results on Apr 23, 2026

Roche Diagnostics Expands Mass Spectrometry Menu With Steroid Assays Receiving CLIA Moderate Complexity Designation

주주 수익률

주가 변동성